SCHEMBL8534922

SCHEMBL8534922

COc1ccc(C(=O)c2c[nH]c3ccccc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 1.00
TP53 P04637 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
IGF1R P08069 1/20 0.65
MET P08581 1/20 0.65
NPC1 O15118 4/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
RAB9A P51151 2/20 0.65
MAPT P10636 1/20 0.65
GPR84 Q9NQS5 1/20 0.63
TUBB1 Q9H4B7 2/20 0.60
GABRP O00591 1/20 0.60
GABRD O14764 1/20 0.60
GABRA1 P14867 1/20 0.60
GABRB1 P18505 1/20 0.60
GABRG2 P18507 1/20 0.60
GABRB3 P28472 1/20 0.60
GABRA5 P31644 1/20 0.60
GABRA3 P34903 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethoxycarbonyl Group SCHEMBL27597866 0.88 SMN1; SMN2 (0.77) SMN1; SMN2TP53NPSR1IGF1RMET
SCHEMBL21439506 0.85 TP53 (0.74) SMN1; SMN2TP53NPSR1IGF1RMET
SCHEMBL28386254 0.85 NPSR1 (0.74) SMN1; SMN2TP53NPSR1NPC1MEN1
SCHEMBL10646231 0.85 SMN1; SMN2 (0.73) SMN1; SMN2TP53NPSR1IGF1RMET
SCHEMBL10646985 0.85 SMN1; SMN2 (0.73) SMN1; SMN2TP53NPSR1IGF1RMET
SCHEMBL8792509 0.85 SMN1; SMN2 (0.73) SMN1; SMN2TP53NPSR1IGF1RMET
SCHEMBL13302221 0.84 NPSR1 (0.72) SMN1; SMN2TP53NPSR1IGF1RMET
SCHEMBL15979987 0.83 CTNNB1 (0.72) SMN1; SMN2TP53NPSR1IGF1RMET
SCHEMBL2980233 0.83 SMN1; SMN2 (0.71) SMN1; SMN2TP53NPSR1IGF1RMET
SCHEMBL1563040 0.83 TUBB1 (0.78) SMN1; SMN2TP53NPSR1NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0149419-B1 ACYLINDOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1988-08-17 EP claimed
US-4708961-A ANTICOAGULANTS NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1987-11-24 US claimed
EP-0149419-A1 Acylindole derivatives and pharmaceutical compositions containing them NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1985-07-24 EP claimed
JP-60072861-A None JP disclosed
JP-61047462-A None JP disclosed
EP-3774767-B1 ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF BETH ISRAEL DEACONESS MEDICAL CT INC (US) 2025-10-29 EP disclosed
US-12152016-B2 Aryl hydrocarbon receptor modulators and uses thereof BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2024-11-26 US disclosed
US-20230278986-A1 ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2023-09-07 US disclosed
US-20230278986-A1 ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2023-09-07 US disclosed
US-20230278986-A1 ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2023-09-07 US disclosed
US-11634408-B2 Aryl hydrocarbon receptor modulators and uses thereof BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2023-04-25 US disclosed
US-RE32761-E ANALGESICS, ANTIRHEUMATIC AND ANTIINFLAMMATORY AGENT STERLING DRUG INC. (US) 1988-10-04 US disclosed
EP-0149419-B1 ACYLINDOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1988-08-17 EP disclosed
US-4708961-A ANTICOAGULANTS NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1987-11-24 US disclosed
US-4634776-A ANALGESIC, ANTIRHEUMATIC, ANTIINFLAMMATORY STERLING DRUG, INC. (US) 1987-01-06 US disclosed
US-4581354-A ANALGESICS;ANTI-RHEUMATIC AND ANTI-INFLAMMATORY AGENTS STERLING DRUG INC. (US) 1986-04-08 US disclosed
JP-S6147462-A NOVEL ACYLINDOLE DERIVATIVE AND BLOOD PLATELET AGGLUTINATION INHIBITOR CONTAINING SAID COMPOUND AS ACTIVE CONSTITUENT NIPPON ZOKI PHARMACEUT CO LTD 1986-03-07 JP disclosed
EP-0171037-A2 3-Carbonyl-1-aminoalkyl-1H-indoles useful as analgesics and preparation thereof STERLING WINTHROP INC. (US) 1986-02-12 EP disclosed
EP-0149419-A1 Acylindole derivatives and pharmaceutical compositions containing them NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1985-07-24 EP disclosed
JP-S6072861-A NOVEL ACYLINDOLE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME NIPPON ZOKI PHARMACEUT CO LTD 1985-04-24 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11634408-B2 Aryl hydrocarbon receptor modulators and uses thereof AHR, ARNT, NR4A1 SMN1; SMN2 4031/4885TP53 1653/4885NPSR1 275/4885
US-20230278986-A1 ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF AHR, ARNT, NR4A1 SMN1; SMN2 4063/4885TP53 1611/4885NPSR1 267/4885
US-12152016-B2 Aryl hydrocarbon receptor modulators and uses thereof AHR, ARNT, NR4A1 SMN1; SMN2 4031/4885TP53 1653/4885NPSR1 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.